A Phase 3 interventional study of Tolvaptan and Tolvaptan Matching-placebo in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 20 sites in 4 countries. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-01-03.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 9th largest by enrollment, is one of 2 that started in 2016, is one of 8 in phase 3, and was the 14th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 4 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2016.
This study's enrollment of 91 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 91 across the 18 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 16 finished, 13 (81%) have results posted.
Among the 17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd., this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2016, is one of 7 in phase 3, and was the 15th registered.
Otsuka Holdings Co., Ltd.’s Polycystic Kidney, Autosomal Dominant studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Polycystic Kidney, Autosomal Dominant:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to assess the long term safety of treatment with tolvaptan in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD). The secondary objective is to assess the pharmacodynamics, pharmacokinetics, and efficacy of tolvaptan in the same participant population.
Tolvaptan has been demonstrated to delay the decline of kidney function in adults with rapidly progressing ADPKD (chronic kidney disease [CKD] stages 1 to 3) as measured by estimated glomerular filtration rate (eGFR) and Total Kidney Volume (TKV).
This trial will be the first trial of tolvaptan in children and adolescents with ADPKD.
Participants in this study will be randomly assigned to one of two groups in Phase A; tolvaptan or placebo. Participants will have an equal chance of being assigned to either treatment group and will be stratified by age and gender into the following cohorts:
Phase (A) of this study will last 12 months. After that time, all participants who qualify will be assigned tolvaptan and will be treated with tolvaptan for 24 months (Phase B).
A qualified participant is defined as one who has completed Phase A on investigational medicinal product (IMP), is willing to continue in the trial, and who does not have any adverse events (AEs), which would require IMP discontinuation.
Participants in this study will be required to make monthly visits to the study clinic and will be closely monitored over the course of the study.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), and starting doses based on their weight as per the following specifications: ≥20 to 45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 12 months. Doses may be titrated down dependent upon participant tolerability.
Drug: Tolvaptan
Participants received matching-placebo tablets, orally as a split-dose (with the first dose taken upon awakening and second dose taken approximately 8 hours later), and starting dose based on their weight as per the following specifications: ≥20 to \<45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 12 months. Doses may be titrated down dependent upon participant tolerability.
Drug: Tolvaptan Matching-placebo
Qualified participants (defined as those who were willing to continue in the trial and who did not have any adverse events \[AEs\] that would require investigational medicinal product \[IMP\] discontinuation) who received tolvaptan and completed Phase A were enrolled in Phase B and received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), and starting dose based on their body weight as per following specifications: ≥20 to \<45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 24 months. Doses may be titrated down dependent upon participant tolerability.
Drug: Tolvaptan
Qualified participants (defined as those who were willing to continue in the trial and who did not have any AEs that would require IMP discontinuation) who received matching-placebo and completed Phase A, were enrolled in Phase B and received tolvaptan tablets, orally as a split dose (with the first dose taken upon awakening and the second dose taken approximately 8 hours later), based on their current body weight as per following specifications: ≥20 to \<45 kg: 15/7.5 mg; ≥45 to ≤75 kg: 30/15 mg; \>75 kg: 45/15 mg, for 1 week. The starting dose was up-titrated (≥20 to \<45 kg: 30/15 mg; ≥45 to ≤75 kg: 45/15 mg; \>75 kg: 60/30 mg) after 1 week based upon tolerability and thereafter participants continued the same dose for 24 months. Doses may be titrated down dependent upon participant tolerability.
Drug: Tolvaptan
Tolvaptan spray-dried, immediate release tablets
Also known as: OPC-41061
Tolvaptan matching-placebo tablets
Phase A: Change From Baseline in Spot Urine Osmolality (Pre-morning Dose)
Urine osmolality is a measure of urine concentration, measured by osmometer, which evaluates the freezing point depression of a solution and supplies results as milliosmoles per kilogram of water. Spot urine osmolality was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), and Week 1 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. All participants were fasting.
Time frame: Baseline, and Week 1 of Phase A
Phase A: Change From Baseline in Specific Gravity (Pre-morning Dose)
Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Spot urine sample for determination of specific gravity was collected immediately prior to morning dosing for Day 1 (Baseline), and Week 1 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. All participants were fasting.
Time frame: Baseline, and Week 1 of Phase A
Phase A: Percent Change From Phase A Baseline in Height-Adjusted Total Kidney Volume (htTKV) as Measured by Magnetic Resonance Imaging (MRI)
htTKV is used in participants with autosomal dominant polycystic kidney disease to predict the onset of renal insufficiency.
Time frame: Baseline, and Month 12 of Phase A
Phase A and B: Mean 24-hour Fluid Balance Prior to Week 1
Participants were instructed to record all fluid taken and all urine output for the 24-hour period.
Time frame: Prior to Week 1 in Phase A and B
Phase A: Change From Baseline in Renal Function (Estimated Glomerular Filtration Rate [eGFR] by Schwartz Formula) at Each Clinic Visit in Phase A
Renal function was assessed by estimated eGFR calculated by the Schwartz formula (eGFR = 0.413 × height \[cm\] /serum creatinine mg/dL), expressed as mean change in eGFR at the specified time points. The units for the data reported are milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2). The baseline was the evaluation done at Week 1 in Phase A for this outcome measure.
Time frame: Phase A Baseline, Months 1, 6, and 12
Phase B: Change From Phase B Baseline in Renal Function (eGFR by Schwartz Formula) at Each Clinic Visit in Phase B
Renal function was assessed by estimated eGFR calculated by the Schwartz formula (eGFR = 0.413 × height \[cm\] /serum creatinine mg/dL), expressed as mean change in eGFR at the specified time points.
Time frame: Phase B Baseline, Week 1, Months 1, 6, 12, 18, and 24
Phase B: Percent Change From Phase B Baseline in htTKV as Measured by MRI at Month 12 and Month 24
htTKV is used in participants with autosomal dominant polycystic kidney disease to predict the onset of renal insufficiency.
Time frame: Phase B Baseline, Months 12 and 24
Phase A: 24-hour Urine Volume
Urine volume refers to the quantity of urine produced per unit of time.
Time frame: 24 hours post dose after Month 1 on study medication in Phase A
Phase A: 24-hour Fluid Intake
Daily fluid intake (total water) is defined as the amount of water consumed from foods, plain drinking water, and other beverages.
Time frame: 24 hours post dose after Month 1 on study medication in Phase A
Phase A: 24-hour Fluid Balance
Fluid balance is a term used to describe the balance of the input and output of fluids in the body to allow metabolic processes to function correctly.
Time frame: 24 hours post dose after Month 1 on study medication in Phase A
Phase A: 24-hour Sodium Clearance
Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.
Time frame: 24 hours post dose after Month 1 on study medication in Phase A
Phase A: 24-hour Creatinine Clearance
Creatinine is produced from the metabolism of protein, when muscles burn energy. Most creatinine is filtered out of the blood by the kidneys and excreted in urine. The creatinine clearance value is determined by measuring the concentration of endogenous creatinine (that which is produced by the body) in both plasma and urine. Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.
Time frame: 24 hours post dose after Month 1 on study medication in Phase A
Phase A: 24-hour Free Water Clearance
Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.
Time frame: 24 hours post dose after Month 1 on study medication in Phase A
Phase A: Percentage of Each Tanner Stage by Gender and Age Compared to Normative Populations
Tanner stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Only those categories with at least one participant with event are reported.
Time frame: At Baseline, Months 6 and 12 of Phase A
Phase B: Percentage of Each Tanner Stage by Gender and Age Compared to Normative Populations
Tanner stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Only those categories with at least one participant with event are reported.
Time frame: At Baseline, Months 6, 12, 18, and 24 of Phase B
Phase A: Change From Baseline in Growth Percentile by Gender and Age
The growth percentile was based on the assessment of height and weight.
Time frame: At Baseline, Months 6 and 12 of Phase A
Phase B: Change From Baseline in Growth Percentile by Gender and Age
The growth percentile was based on the assessment of height and weight.
Time frame: At Baseline, Months 6, 12, 18, and 24 of Phase B
Phase A: Change From Baseline in Creatinine Value
Phase A Baseline is the last pre-dose evaluation. The Last Visit is the last available post-baseline evaluation including early term. As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan and Phase A: Placebo)
Time frame: Baseline, Week 1, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, Follow Up Day 7, End of Treatment, and Last Visit
Phase B: Change From Baseline in Creatinine Value
Phase B Baseline is the last evaluation prior to the first dose in Phase B. The Last Visit is the last available post-baseline evaluation including early term. As prespecified in the protocol, data for safety is reported by the treatment group (Phase B: Prior Tolvaptan and Phase B: Prior Placebo).
Time frame: Baseline, Week 1, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, Follow Up Day 7, End of Treatment, and Last Visit
Phase A and B: Percentage of Participants With Potentially Clinically Significant Abnormalities in Vital Signs
Vital sign measurements included measurements of respiratory rate, blood pressure, body temperature and pulse. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance. Only those categories with at least one participant with event are reported. As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan, Phase A: Placebo, Phase B: Prior Tolvaptan and Phase B: Prior Placebo).
Time frame: From first dose of study drug up to 14 days post last dose (up to approximately 37 months)
Phase A and B: Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Test Results Including Liver Function Tests (LFTs)
Laboratory parameters=haematology,chemistry,urinalysis,\& LFTs.Criteria for laboratory abnormalities along with their test result grade=Increased creatinine level: Baseline(BSL):Grade 0,\>BSL-1.5xBSL:1,\>1.5-3xBSL:2,\>3-6xBSL:3,\>6xBSL:4.Decreased glucose level: \<30:-4,30-\<40:-3, 40-\<55:-2, 55-\<65:-1,\>=65:0; Increased:\<=115:0,\>115-160:1,\>160-250:2,\>250-500:3,\>500:4.Decreased potassium level: \<2.5:-4,2.5-\<3:-3,3-\<lower limit of normal(LLN):-1,LLN:0; Increased:upper limit of normal(ULN):0,\>ULN-5.5:1,\>5.5-6:2,\>6-7:3,\>7:4.Decreased sodium level: \<120:-4,120-124:-3,125-129:-2,130-135:-1,\>=136:0; Increased:\<=145:0,146-150:1,151-155:2,156-160:3,\>160:4. Increased triglyceride level:ULN:0,\>ULN-2.5xULN:1,\>2.5-5xULN:2,\>5-6xULN:3,\>6xULN:4. Decreased Neutrophils:\<0.5:-4,0.5-\<1:-3,1-\<1.5:-2,1.5-\<LLN:-1,LLN:0. Potentially clinically significant increase or decrease was defined as Baseline grade 0,1,-1 and post-baseline grade \>1, \<-1 or Baseline grade \>1,\<-1 and post-baseline grade \>or\<Baseline grade.
Time frame: From first dose of study drug up to 14 days post last dose (up to approximately 37 months)
Phase A and B: Percentage of Participants With Aquaretic Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Aquaretic AEs included Medical Dictionary for Regulatory Activities \[MedDRA\] preferred terms of thirst, polyuria (production of large volumes of dilute urine), nocturia (need to wake up to urinate at night), pollakiuria (abnormally frequent urination), and polydipsia (excessive thirst). As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan, Phase A: Placebo, Phase B: Prior Tolvaptan and Phase B: Prior Placebo).
Time frame: From first dose of study drug up to 14 days post last dose (up to approximately 37 months)
Participants took part in the study at 18 sites in Belgium, Germany, Italy, and the United Kingdom from 23 September 2016 to 17 November 2021.
| Milestone | Phase A: Tolvaptan | Phase A: Placebo | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|---|---|
| Started | 48 | 43 | 0 | 0 |
| Dense pharmacokinetic/pharmacodynamic (pk/pd) population | 12 | 8 | 0 | 0 |
| Completed | 44 | 40 | 0 | 0 |
| Not completed | 4 | 3 | 0 | 0 |
| Withdrew: Adverse events | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 | 0 |
| Milestone | Phase A: Tolvaptan | Phase A: Placebo | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|---|---|
| Started | 0 | 0 | 42 | 39 |
| Completed | 0 | 0 | 36 | 33 |
| Not completed | 0 | 0 | 6 | 6 |
| Withdrew: Adverse events | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 | 3 |
| Withdrew: Reason not specified | 0 | 0 | 2 | 1 |
Urine osmolality is a measure of urine concentration, measured by osmometer, which evaluates the freezing point depression of a solution and supplies results as milliosmoles per kilogram of water. Spot urine osmolality was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), and Week 1 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. All participants were fasting.
| milliosmoles per kilogram (mOsm/kg) | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Baseline | 635 ± 252 | 646 ± 250 |
| Change From Baseline at Week 1, Phase A | -386 ± 284 | -93 ± 332 |
Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Spot urine sample for determination of specific gravity was collected immediately prior to morning dosing for Day 1 (Baseline), and Week 1 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. All participants were fasting.
| ratio | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Baseline | 1.017 ± 0.006 | 1.017 ± 0.006 |
| Change From Baseline at Week 1, Phase A | -0.009 ± 0.007 | -0.002 ± 0.008 |
htTKV is used in participants with autosomal dominant polycystic kidney disease to predict the onset of renal insufficiency.
| percent change | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Phase A: Percent Change From Phase A Baseline in Height-Adjusted Total Kidney Volume (htTKV) as Measured by Magnetic Resonance Imaging (MRI) | 2.28 ± 8.75 | 6.11 ± 7.48 |
Participants were instructed to record all fluid taken and all urine output for the 24-hour period.
| milliliter | Phase A: Tolvaptan | Phase A: Placebo | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|---|---|
| Phase A and B: Mean 24-hour Fluid Balance Prior to Week 1 | 31 ± 1978 | 241 ± 867 | 138 ± 1382 | 207 ± 1355 |
Renal function was assessed by estimated eGFR calculated by the Schwartz formula (eGFR = 0.413 × height \[cm\] /serum creatinine mg/dL), expressed as mean change in eGFR at the specified time points. The units for the data reported are milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2). The baseline was the evaluation done at Week 1 in Phase A for this outcome measure.
| mL/min/1.73 m^2 | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Baseline | 93.9 ± 18.7 | 102.1 ± 15.4 |
| Change From Baseline at Month 1, Phase A | 2.8 ± 10.7 | -1.9 ± 8.8 |
| Change From Baseline at Month 6, Phase A | 4.6 ± 10.1 | -2.5 ± 11.1 |
| Change From Baseline at Month 12, Phase A | 2.6 ± 10.7 | -3.2 ± 10.9 |
Renal function was assessed by estimated eGFR calculated by the Schwartz formula (eGFR = 0.413 × height \[cm\] /serum creatinine mg/dL), expressed as mean change in eGFR at the specified time points.
| mL/min/1.73 m^2 | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|
| Phase B Baseline | 97.0 ± 17.1 | 98.5 ± 14.1 |
| Change From Phase B Baseline at Week 1, Phase B | -1.7 ± 10.4 | -6.7 ± 8.0 |
| Change From Phase B Baseline at Month 1, Phase B | -0.9 ± 10.2 | -4.8 ± 9.0 |
| Change From Phase B Baseline at Month 6, Phase B | -4.2 ± 9.6 | -6.4 ± 7.9 |
| Change From Phase B Baseline at Month 12, Phase B | -5.6 ± 11.1 | -7.2 ± 9.3 |
| Change From Phase B Baseline at Month 18, Phase B | -3.5 ± 9.8 | -9.0 ± 10.9 |
| Change From Phase B Baseline at Month 24, Phase B | -5.2 ± 9.4 | -10.3 ± 11.0 |
htTKV is used in participants with autosomal dominant polycystic kidney disease to predict the onset of renal insufficiency.
| percent change | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|
| Percent Change From Phase B Baseline at Month 12, Phase B | 7.68 ± 9.67 | 3.09 ± 8.97 |
| Percent Change From Phase B Baseline at Month 24 Phase B | 13.55 ± 12.88 | 7.35 ± 9.57 |
Urine volume refers to the quantity of urine produced per unit of time.
| milliliter per 24 hours post dose | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Phase A: 24-hour Urine Volume | 7171 ± 2810 | 2529 ± 2164 |
Daily fluid intake (total water) is defined as the amount of water consumed from foods, plain drinking water, and other beverages.
| milliliter | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Phase A: 24-hour Fluid Intake | 7486 ± 2350 | 3156 ± 1775 |
Fluid balance is a term used to describe the balance of the input and output of fluids in the body to allow metabolic processes to function correctly.
| milliliter | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Phase A: 24-hour Fluid Balance | 53 ± 1894 | 230 ± 1254 |
Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.
| milliliter per minute (mL/min) | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Total Daily Dose: 37.5 mg | 0.8 ± 0.3 | — |
| Total Daily Dose: 45 mg | 0.7 ± 0.3 | — |
| Total Daily Dose: 60 mg | 0.9 ± 0.3 | — |
| Total Daily Dose: Placebo | — | 0.7 ± 0.5 |
Creatinine is produced from the metabolism of protein, when muscles burn energy. Most creatinine is filtered out of the blood by the kidneys and excreted in urine. The creatinine clearance value is determined by measuring the concentration of endogenous creatinine (that which is produced by the body) in both plasma and urine. Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.
| mL/min | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Total Daily Dose: 22.5 mg | 124.6 ± NA | — |
| Total Daily Dose: 37.5 mg | 148.5 ± 23.4 | — |
| Total Daily Dose: 45 mg | 95.0 ± 10.1 | — |
| Total Daily Dose: 60 mg | 123.7 ± 23.2 | — |
| Total Daily Dose: Placebo | — | 105.1 ± 51.7 |
Data was categorized and reported based on the total daily dose for the given time point of 0-24 hours.
| mL/min | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Total Daily Dose: 37.5 mg | 2.3 ± 0.9 | — |
| Total Daily Dose: 45 mg | 2.6 ± 0.9 | — |
| Total Daily Dose: 60 mg | 3.0 ± 1.2 | — |
| Total Daily Dose: Placebo | — | 0.1 ± 1.2 |
Tanner stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Only those categories with at least one participant with event are reported.
| percentage of participants | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Female (>=4 to <12 Years): Baseline- Stage 1 | 6.3 | 11.6 |
| Female (>=4 to <12 Years): Baseline- Stage 3 | 0.0 | 2.3 |
| Female (>=4 to <12 Years): Month 6, Phase A- Stage 1 | 6.3 | 9.3 |
| Female (>=4 to <12 Years): Month 6, Phase A- Stage 2 | 0.0 | 2.3 |
| Female (>=4 to <12 Years): Month 6, Phase A- Stage 4 | 0.0 | 2.3 |
| Female (>=4 to <12 Years): Month 12, Phase A- Stage 1 | 4.2 | 7.0 |
| Female (>=4 to <12 Years): Month 12, Phase A- Stage 2 | 0.0 | 2.3 |
| Female (>=4 to <12 Years): Month 12, Phase A- Stage 4 | 0.0 | 2.3 |
| Male (>=4 to <12 Years): Baseline- Stage 1 | 16.7 | 4.7 |
| Male (>=4 to <12 Years): Baseline- Stage 2 | 0.0 | 4.7 |
| Male (>=4 to <12 Years): Baseline- Stage 3 | 2.1 | 0.0 |
| Male (>=4 to <12 Years): Month 6, Phase A- Stage 1 | 16.7 | 7.0 |
| Male (>=4 to <12 Years): Month 6, Phase A- Stage 2 | 2.1 | 0.0 |
| Male (>=4 to <12 Years): Month 6, Phase A- Stage 3 | 2.1 | 4.7 |
| Male (>=4 to <12 Years): Month 12, Phase A- Stage 1 | 14.6 | 4.7 |
| Male (>=4 to <12 Years): Month 12, Phase A- Stage 2 | 4.2 | 2.3 |
| Male (>=4 to <12 Years): Month 12, Phase A- Stage 3 | 0.0 | 4.7 |
| Male (>=4 to <12 Years): Month 12, Phase A- Stage 4 | 2.1 | 0.0 |
| Female (>=12 to <15 Years): Baseline- Stage 1 | 2.1 | 0.0 |
| Female (>=12 to <15 Years): Baseline- Stage 2 | 0.0 | 4.7 |
| Female (>=12 to <15 Years): Baseline- Stage 3 | 2.1 | 2.3 |
| Female (>=12 to <15 Years): Baseline- Stage 4 | 4.2 | 0.0 |
| Female (>=12 to <15 Years): Baseline- Stage 5 | 10.4 | 7.0 |
| Female (>=12 to <15 Years): Month 6, Phase A- Stage 2 | 0.0 | 2.3 |
| Female (>=12 to <15 Years): Month 6, Phase A- Stage 3 | 0.0 | 2.3 |
| Female (>=12 to <15 Years): Month 6, Phase A- Stage 4 | 2.1 | 0.0 |
| Female (>=12 to <15 Years): Month 6, Phase A- Stage 5 | 12.5 | 7.0 |
| Female (>=12 to <15 Years): Month 12, Phase A- Stage 2 | 0.0 | 2.3 |
| Female (>=12 to <15 Years): Month 12, Phase A- Stage 3 | 0.0 | 2.3 |
| Female (>=12 to <15 Years): Month 12, Phase A- Stage 4 | 0.0 | 4.7 |
| Female (>=12 to <15 Years): Month 12, Phase A- Stage 5 | 14.6 | 9.3 |
| Male (>=12 to <15 Years): Baseline- Stage 2 | 6.3 | 4.7 |
| Male (>=12 to <15 Years): Baseline- Stage 3 | 4.2 | 4.7 |
| Male (>=12 to <15 Years): Baseline- Stage 4 | 2.1 | 4.7 |
| Male (>=12 to <15 Years): Baseline- Stage 5 | 2.1 | 2.3 |
| Male (>=12 to <15 Years): Month 6, Phase A- Stage 2 | 4.2 | 2.3 |
| Male (>=12 to <15 Years): Month 6, Phase A- Stage 3 | 4.2 | 2.3 |
| Male (>=12 to <15 Years): Month 6, Phase A- Stage 4 | 4.2 | 4.7 |
| Male (>=12 to <15 Years): Month 6, Phase A- Stage 5 | 2.1 | 2.3 |
| Male (>=12 to <15 Years): Month 12, Phase A- Stage 2 | 0.0 | 2.3 |
| Male (>=12 to <15 Years): Month 12, Phase A- Stage 3 | 2.1 | 0.0 |
| Male (>=12 to <15 Years): Month 12, Phase A- Stage 4 | 8.3 | 7.0 |
| Male (>=12 to <15 Years): Month 12, Phase A- Stage 5 | 4.2 | 2.3 |
| Male (>=12 to <15 Years): End of Treatment- Stage 5 | 2.1 | 2.3 |
| Female (>=15 to <18 Years): Baseline- Stage 4 | 2.1 | 0.0 |
| Female (>=15 to <18 Years): Baseline- Stage 5 | 12.5 | 18.6 |
| Female (>=15 to <18 Years): Month 6, Phase A- Stage 4 | 2.1 | 0.0 |
| Female (>=15 to <18 Years): Month 6, Phase A- Stage 5 | 12.5 | 16.3 |
| Female (>=15 to <18 Years): Month 12, Phase A- Stage 4 | 2.1 | 0.0 |
| Female (>=15 to <18 Years): Month 12, Phase A- Stage 5 | 14.6 | 16.3 |
| Female (>=15 to <18 Years): End of Treatment- Stage 5 | 0.0 | 2.3 |
| Male (>=15 to <18 Years): Baseline- Stage 4 | 2.1 | 4.7 |
| Male (>=15 to <18 Years): Baseline- Stage 5 | 16.7 | 14.0 |
| Male (>=15 to <18 Years): Month 6, Phase A- Stage 4 | 2.1 | 2.3 |
| Male (>=15 to <18 Years): Month 6, Phase A- Stage 5 | 14.6 | 16.3 |
| Male (>=15 to <18 Years): Month 12, Phase A- Stage 4 | 2.1 | 0.0 |
| Male (>=15 to <18 Years): Month 12, Phase A- Stage 5 | 14.6 | 18.6 |
| Male (>=15 to <18 Years): End of Treatment- Stage 5 | 2.1 | 0.0 |
Tanner stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Only those categories with at least one participant with event are reported.
| percentage of participants | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|
| Female (>=4 to <12 Years): Phase B Baseline- Stage 1 | 7.1 | 10.3 |
| Female (>=4 to <12 Years): Phase B Baseline- Stage 2 | 0.0 | 2.6 |
| Female (>=4 to <12 Years): Phase B Baseline- Stage 4 | 0.0 | 2.6 |
| Female (>=4 to <12 Years): Month 6, Phase B- Stage 1 | 4.8 | 7.7 |
| Female (>=4 to <12 Years): Month 6, Phase B- Stage 2 | 0.0 | 2.6 |
| Female (>=4 to <12 Years): Month 6, Phase B- Stage 4 | 0.0 | 2.6 |
| Female (>=4 to <12 Years): Month 12, Phase B- Stage 1 | 4.8 | 7.7 |
| Female (>=4 to <12 Years): Month 12, Phase B- Stage 2 | 0.0 | 2.6 |
| Female (>=4 to <12 Years): Month 12, Phase B- Stage 3 | 0.0 | 2.6 |
| Female (>=4 to <12 Years): Month 12, Phase B- Stage 4 | 0.0 | 2.6 |
| Female (>=4 to <12 Years): Month 18, Phase B- Stage 1 | 4.8 | 2.6 |
| Female (>=4 to <12 Years): Month 18, Phase B- Stage 2 | 0.0 | 7.7 |
| Female (>=4 to <12 Years): Month 18, Phase B- Stage 4 | 0.0 | 2.6 |
| Female (>=4 to <12 Years): Month 24, Phase B- Stage 1 | 2.4 | 2.6 |
| Female (>=4 to <12 Years): Month 24, Phase B- Stage 2 | 2.4 | 5.1 |
| Female (>=4 to <12 Years): Month 24, Phase B- Stage 3 | 0.0 | 2.6 |
| Female (>=4 to <12 Years): Month 24, Phase B- Stage 4 | 0.0 | 2.6 |
| Male (>=4 to <12 Years): Phase B Baseline- Stage 1 | 11.9 | 5.1 |
| Male (>=4 to <12 Years): Phase B Baseline- Stage 2 | 4.8 | 2.6 |
| Male (>=4 to <12 Years): Phase B Baseline- Stage 3 | 0.0 | 5.1 |
| Male (>=4 to <12 Years): Phase B Baseline- Stage 4 | 2.4 | 0.0 |
| Male (>=4 to <12 Years): Month 6, Phase B- Stage 1 | 9.5 | 2.6 |
| Male (>=4 to <12 Years): Month 6, Phase B- Stage 2 | 2.4 | 2.6 |
| Male (>=4 to <12 Years): Month 6, Phase B- Stage 3 | 2.4 | 2.6 |
| Male (>=4 to <12 Years): Month 6, Phase B- Stage 4 | 2.4 | 2.6 |
| Male (>=4 to <12 Years): Month 12, Phase B- Stage 1 | 9.5 | 2.6 |
| Male (>=4 to <12 Years): Month 12, Phase B- Stage 2 | 2.4 | 0.0 |
| Male (>=4 to <12 Years): Month 12, Phase B- Stage 3 | 2.4 | 5.1 |
| Male (>=4 to <12 Years): Month 12, Phase B- Stage 4 | 2.4 | 2.6 |
| Male (>=4 to <12 Years): Month 18, Phase B- Stage 1 | 4.8 | 2.6 |
| Male (>=4 to <12 Years): Month 18, Phase B- Stage 2 | 2.4 | 0.0 |
| Male (>=4 to <12 Years): Month 18, Phase B- Stage 3 | 0.0 | 5.1 |
| Male (>=4 to <12 Years): Month 18, Phase B- Stage 4 | 4.8 | 0.0 |
| Male (>=4 to <12 Years): Month 18, Phase B- Stage 5 | 0.0 | 2.6 |
| Male (>=4 to <12 Years): Month 24, Phase B- Stage 1 | 4.8 | 0.0 |
| Male (>=4 to <12 Years): Month 24, Phase B- Stage 2 | 4.8 | 0.0 |
| Male (>=4 to <12 Years): Month 24, Phase B- Stage 3 | 2.4 | 5.1 |
| Male (>=4 to <12 Years): Month 24, Phase B- Stage 4 | 2.4 | 0.0 |
| Male (>=4 to <12 Years): Month 24, Phase B- Stage 5 | 2.4 | 2.6 |
| Female (>=12 to <15 Years): Phase B Baseline- Stage 2 | 0.0 | 2.6 |
| Female (>=12 to <15 Years): Phase B Baseline- Stage 3 | 0.0 | 2.6 |
| Female (>=12 to <15 Years): Phase B Baseline- Stage 4 | 0.0 | 5.1 |
| Female (>=12 to <15 Years): Phase B Baseline- Stage 5 | 16.7 | 10.3 |
| Female (>=12 to <15 Years): Month 6, Phase B- Stage 3 | 0.0 | 5.1 |
| Female (>=12 to <15 Years): Month 6, Phase B- Stage 4 | 0.0 | 5.1 |
| Female (>=12 to <15 Years): Month 6, Phase B-Stage 5 | 16.7 | 10.3 |
| Female (>=12 to <15 Years): Month 12, Phase B- Stage 4 | 0.0 | 5.1 |
| Female (>=12 to <15 Years): Month 12, Phase B- Stage 5 | 14.3 | 10.3 |
| Female (>=12 to <15 Years): Month 18, Phase B- Stage 4 | 0.0 | 2.6 |
| Female (>=12 to <15 Years): Month 18, Phase B- Stage 5 | 11.9 | 10.3 |
| Female (>=12 to <15 Years): Month 24, Phase B- Stage 4 | 0.0 | 5.1 |
| Female (>=12 to <15 Years): Month 24, Phase B- Stage 5 | 9.5 | 10.3 |
| Female (>=12 to <15 Years): End of Treatment, Phase B- Stage 4 | 0.0 | 2.6 |
| Female (>=12 to <15 Years): End of Treatment, Phase B- Stage 5 | 7.1 | 2.6 |
| Male (>=12 to <15 Years): Phase B Baseline- Stage 2 | 0.0 | 2.6 |
| Male (>=12 to <15 Years): Phase B Baseline- Stage 3 | 2.4 | 0.0 |
| Male (>=12 to <15 Years): Phase B Baseline- Stage 4 | 9.5 | 7.7 |
| Male (>=12 to <15 Years): Phase B Baseline- Stage 5 | 4.8 | 2.6 |
| Male (>=12 to <15 Years): Month 6, Phase B- Stage 2 | 0.0 | 2.6 |
| Male (>=12 to <15 Years): Month 6, Phase B- Stage 3 | 2.4 | 0.0 |
| Male (>=12 to <15 Years): Month 6, Phase B- Stage 4 | 4.8 | 5.1 |
| Male (>=12 to <15 Years): Month 6, Phase B- Stage 5 | 4.8 | 2.6 |
| Male (>=12 to <15 Years): Month 12, Phase B- Stage 2 | 0.0 | 2.6 |
| Male (>=12 to <15 Years): Month 12, Phase B- Stage 4 | 7.1 | 5.1 |
| Male (>=12 to <15 Years): Month 12, Phase B- Stage 5 | 7.1 | 5.1 |
| Male (>=12 to <15 Years): Month 18, Phase B- Stage 2 | 0.0 | 2.6 |
| Male (>=12 to <15 Years): Month 18, Phase B- Stage 4 | 4.8 | 0.0 |
| Male (>=12 to <15 Years): Month 18, Phase B- Stage 5 | 9.5 | 7.7 |
| Male (>=12 to <15 Years): Month 24, Phase B- Stage 2 | 0.0 | 2.6 |
| Male (>=12 to <15 Years): Month 24, Phase B- Stage 4 | 4.8 | 0.0 |
| Male (>=12 to <15 Years): Month 24, Phase B- Stage 5 | 9.5 | 10.3 |
| Male (>=12 to <15 Years): End of Treatment, Phase B- Stage 5 | 0.0 | 2.6 |
| Female (>=15 to <18 Years): Phase B Baseline- Stage 4 | 2.4 | 0.0 |
| Female (>=15 to <18 Years): Phase B Baseline- Stage 5 | 16.7 | 15.4 |
| Female (>=15 to <18 Years): Month 6, Phase B- Stage 4 | 2.4 | 0.0 |
| Female (>=15 to <18 Years): Month 6, Phase B- Stage 5 | 16.7 | 12.8 |
| Female (>=15 to <18 Years): Month 12, Phase B- Stage 4 | 2.4 | 0.0 |
| Female (>=15 to <18 Years): Month 12, Phase B- Stage 5 | 16.7 | 12.8 |
| Female (>=15 to <18 Years): Month 18, Phase B- Stage 4 | 2.4 | 0.0 |
| Female (>=15 to <18 Years): Month 18, Phase B- Stage 5 | 16.7 | 12.8 |
| Female (>=15 to <18 Years): Month 24, Phase B- Stage 4 | 2.4 | 0.0 |
| Female (>=15 to <18 Years): Month 24, Phase B- Stage 5 | 16.7 | 12.8 |
| Female (>=15 to <18 Years): End of Treatment, Phase B- Stage 5 | 0.0 | 5.1 |
| Male (>=15 to <18 Years): Phase B Baseline- Stage 4 | 2.4 | 0.0 |
| Male (>=15 to <18 Years): Phase B Baseline- Stage 5 | 16.7 | 20.5 |
| Male (>=15 to <18 Years): Month 6, Phase B- Stage 5 | 19.0 | 17.9 |
| Male (>=15 to <18 Years): Month 12, Phase B- Stage 5 | 16.7 | 17.9 |
| Male (>=15 to <18 Years): Month 18, Phase B- Stage 5 | 16.7 | 15.4 |
| Male (>=15 to <18 Years): Month 24, Phase B- Stage 5 | 16.7 | 12.8 |
| Male (>=15 to <18 Years): End of Treatment, Phase B- Stage 5 | 4.8 | 7.7 |
The growth percentile was based on the assessment of height and weight.
| growth percentile | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Female Participants with Age >=15 to <18 Years - Baseline, Phase A | 62 ± 28 | 60 ± 34 |
| Change From Baseline in Female Participants with Age >=15 to <18 Years - Month 6, Phase A | 2 ± 18 | -2 ± 12 |
| Change From Baseline in Female Participants with Age >=15 to <18 Years - Month 12, Phase A | 7 ± 10 | -5 ± 11 |
| Male Participants with Age >=15 to <18 Years - Baseline, Phase A | 56 ± 29 | 73 ± 18 |
| Change From Baseline in Male Participants with Age >=15 to <18 Years - Month 6, Phase A | 12 ± 16 | -1 ± 30 |
| Change From Baseline in Male Participants with Age >=15 to <18 Years - Month 12, Phase A | 2 ± 37 | -3 ± 25 |
| Female Participants with Age >=12 to <15 Years - Baseline, Phase A | 71 ± 20 | 72 ± 29 |
| Change From Baseline in Female Participants with Age >=12 to <15 Years - Month 6, Phase A | -2 ± 12 | -20 ± 21 |
| Change From Baseline in Female Participants with Age >=12 to <15 Years - Month 12, Phase A | -11 ± 9 | -18 ± 27 |
| Male Participants with Age >=12 to <15 Years - Baseline, Phase A | 70 ± 21 | 76 ± 24 |
| Change From Baseline in Male Participants with Age >=12 to <15 Years - Month 6, Phase A | -7 ± 13 | -13 ± 38 |
| Change From Baseline in Male Participants with Age >=12 to <15 Years - Month 12, Phase A | 0 ± 20 | 8 ± 17 |
| Female Participants with Age 4 to <=11 Years - Baseline, Phase A | 71 ± 25 | 57 ± 14 |
| Change From Baseline in Female Participants with Age 4 to <=11 Years - Month 6, Phase A | -1 ± 3 | 4 ± 16 |
| Change From Baseline in Female Participants with Age 4 to <=11 Years - Month 12, Phase A | 7 ± 15 | 2 ± 18 |
| Male Participants with Age 4 to <=11 Years - Baseline, Phase A | 57 ± 31 | 63 ± 19 |
| Change From Baseline in Male Participants with Age 4 to <=11 Years - Month 6, Phase A | 4 ± 16 | 0 ± 0 |
| Change From Baseline in Male Participants with Age 4 to <=11 Years - Month 12, Phase A | 1 ± 3 | 1 ± 4 |
The growth percentile was based on the assessment of height and weight.
| growth percentile | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|
| Female Participants with Age >=15 to <18 Years - Phase B Baseline | 69 ± 32 | 46 ± 28 |
| Change From Baseline Female Participants with Age >=15 to <18 Years - Month 6, Phase B | -7 ± 17 | 12 ± 21 |
| Change From Baseline Female Participants with Age >=15 to <18 Years - Month 12, Phase B | 0 ± 7 | 20 ± 18 |
| Change From Baseline Female Participants with Age >=15 to <18 Years - Month 18, Phase B | -2 ± 2 | 10 ± 9 |
| Change From Baseline Female Participants with Age >=15 to <18 Years - Month 24, Phase B | 6 ± 16 | 16 ± 20 |
| Male Participants with Age >=15 to <18 Years - Phase B Baseline | 60 ± 34 | 69 ± 18 |
| Change From Baseline Male Participants with Age >=15 to <18 Years - Month 6, Phase B | -13 ± 53 | 1 ± 2 |
| Change From Baseline Male Participants with Age >=15 to <18 Years - Month 12, Phase B | -8 ± 47 | 8 ± 11 |
| Change From Baseline Male Participants with Age >=15 to <18 Years - Month 18, Phase B | 16 ± 65 | -4 ± 25 |
| Change From Baseline Male Participants with Age >=15 to <18 Years - Month 24, Phase B | -2 ± 50 | -11 ± 25 |
| Female Participants with Age >=12 to <15 Years - Phase B Baseline | 62 ± 24 | 54 ± 34 |
| Change From Baseline Female Participants with Age >=12 to <15 Years - Month 6, Phase B | 3 ± 6 | 13 ± 18 |
| Change From Baseline Female Participants with Age >=12 to <15 Years - Month 12, Phase B | 12 ± 20 | 12 ± 23 |
| Change From Baseline Female Participants with Age >=12 to <15 Years - Month 18, Phase B | 5 ± 9 | 10 ± 22 |
| Change From Baseline Female Participants with Age >=12 to <15 Years - Month 24, Phase B | 1 ± 3 | 13 ± 18 |
| Male Participants with Age >=12 to <15 Years - Phase B Baseline | 67 ± 26 | 77 ± 23 |
| Change From Baseline Male Participants with Age >=12 to <15 Years - Month 6, Phase B | 1 ± 10 | -15 ± 38 |
| Change From Baseline Male Participants with Age >=12 to <15 Years - Month 12, Phase B | 4 ± 16 | -23 ± 37 |
| Change From Baseline Male Participants with Age >=12 to <15 Years - Month 18, Phase B | -4 ± 14 | -22 ± 40 |
| Change From Baseline Male Participants with Age >=12 to <15 Years - Month 24, Phase B | -8 ± 15 | -18 ± 36 |
| Female Participants with Age 4 to <=11 Years - Phase B Baseline | 78 ± 19 | 59 ± 22 |
| Change From Baseline Female Participants with Age 4 to <=11 Years - Month 6, Phase B | -2 ± 2 | 2 ± 12 |
| Change From Baseline Female Participants with Age 4 to <=11 Years - Month 12, Phase B | 5 ± 8 | 1 ± 12 |
| Change From Baseline Female Participants with Age 4 to <=11 Years - Month 18, Phase B | -5 ± 6 | 2 ± 23 |
| Change From Baseline Female Participants with Age 4 to <=11 Years - Month 24, Phase B | -4 ± 5 | 10 ± 21 |
| Male Participants with Age 4 to <=11 Years - Phase B Baseline | 65 ± 30 | 64 ± 21 |
| Change From Baseline Male Participants with Age 4 to <=11 Years - Month 6, Phase B | 0 ± 13 | 1 ± 2 |
| Change From Baseline Male Participants with Age 4 to <=11 Years - Month 12, Phase B | 3 ± 20 | 4 ± 8 |
| Change From Baseline Male Participants with Age 4 to <=11 Years - Month 18, Phase B | -4 ± 12 | 2 ± 9 |
| Change From Baseline Male Participants with Age 4 to <=11 Years - Month 24, Phase B | 0 ± 18 | 21 ± 23 |
Phase A Baseline is the last pre-dose evaluation. The Last Visit is the last available post-baseline evaluation including early term. As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan and Phase A: Placebo)
| milligrams per deciliter (mg/dL) | Phase A: Tolvaptan | Phase A: Placebo |
|---|---|---|
| Baseline | 0.70 ± 0.16 | 0.67 ± 0.12 |
| Change From Baseline at Week 1 | 0.04 ± 0.09 | -0.01 ± 0.06 |
| Change From Baseline at Month 1 | 0.01 ± 0.08 | 0.01 ± 0.06 |
| Change From Baseline at Month 2 | 0.01 ± 0.09 | 0.00 ± 0.07 |
| Change From Baseline at Month 3 | 0.00 ± 0.11 | 0.01 ± 0.06 |
| Change From Baseline at Month 4 | 0.00 ± 0.09 | -0.01 ± 0.07 |
| Change From Baseline at Month 5 | 0.01 ± 0.09 | 0.01 ± 0.06 |
| Change From Baseline at Month 6 | 0.01 ± 0.10 | 0.02 ± 0.07 |
| Change From Baseline at Month 7 | 0.01 ± 0.10 | 0.02 ± 0.06 |
| Change From Baseline at Month 8 | 0.01 ± 0.11 | 0.02 ± 0.07 |
| Change From Baseline at Month 9 | 0.04 ± 0.11 | 0.01 ± 0.07 |
| Change From Baseline at Month 10 | 0.01 ± 0.10 | 0.03 ± 0.07 |
| Change From Baseline at Month 11 | 0.02 ± 0.11 | 0.04 ± 0.08 |
| Change From Baseline at Month 12 | 0.02 ± 0.09 | 0.02 ± 0.06 |
| Change From Baseline at Follow Up Day 7 | 0.09 ± NA | -0.02 ± NA |
| Change From Baseline at End of Treatment | 0.03 ± 0.10 | 0.03 ± 0.04 |
| Change From Baseline at Last Visit | 0.03 ± 0.09 | 0.02 ± 0.06 |
Phase B Baseline is the last evaluation prior to the first dose in Phase B. The Last Visit is the last available post-baseline evaluation including early term. As prespecified in the protocol, data for safety is reported by the treatment group (Phase B: Prior Tolvaptan and Phase B: Prior Placebo).
| mg/dL | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|
| Baseline | 0.73 ± 0.17 | 0.69 ± 0.13 |
| Change From Baseline at Week 1 | 0.01 ± 0.06 | 0.04 ± 0.06 |
| Change From Baseline at Month 1 | 0.01 ± 0.07 | 0.04 ± 0.06 |
| Change From Baseline at Month 2 | 0.02 ± 0.07 | 0.04 ± 0.07 |
| Change From Baseline at Month 3 | 0.02 ± 0.07 | 0.04 ± 0.07 |
| Change From Baseline at Month 4 | 0.04 ± 0.06 | 0.05 ± 0.07 |
| Change From Baseline at Month 5 | 0.03 ± 0.06 | 0.07 ± 0.07 |
| Change From Baseline at Month 6 | 0.03 ± 0.07 | 0.06 ± 0.07 |
| Change From Baseline at Month 7 | 0.04 ± 0.07 | 0.06 ± 0.07 |
| Change From Baseline at Month 8 | 0.05 ± 0.08 | 0.07 ± 0.07 |
| Change From Baseline at Month 9 | 0.07 ± 0.11 | 0.09 ± 0.13 |
| Change From Baseline at Month 10 | 0.06 ± 0.07 | 0.06 ± 0.07 |
| Change From Baseline at Month 11 | 0.05 ± 0.07 | 0.08 ± 0.08 |
| Change From Baseline at Month 12 | 0.06 ± 0.12 | 0.07 ± 0.08 |
| Change From Baseline at Month 13 | 0.04 ± 0.08 | 0.08 ± 0.08 |
| Change From Baseline at Month 14 | 0.08 ± 0.07 | 0.08 ± 0.08 |
| Change From Baseline at Month 15 | 0.06 ± 0.07 | 0.06 ± 0.08 |
| Change From Baseline at Month 16 | 0.05 ± 0.08 | 0.08 ± 0.09 |
| Change From Baseline at Month 17 | 0.07 ± 0.08 | 0.08 ± 0.09 |
| Change From Baseline at Month 18 | 0.05 ± 0.09 | 0.09 ± 0.07 |
| Change From Baseline at Month 19 | 0.06 ± 0.10 | 0.09 ± 0.10 |
| Change From Baseline at Month 20 | 0.04 ± 0.08 | 0.11 ± 0.08 |
| Change From Baseline at Month 21 | 0.09 ± 0.12 | 0.09 ± 0.10 |
| Change From Baseline at Month 22 | 0.06 ± 0.08 | 0.09 ± 0.10 |
| Change From Baseline at Month 23 | 0.07 ± 0.06 | 0.12 ± 0.08 |
| Change From Baseline at Month 24 | 0.07 ± 0.08 | 0.12 ± 0.10 |
| Change From Baseline at Follow Up Day 7 | -0.01 ± 0.02 | 0.14 ± 0.08 |
| Change From Baseline at End of Treatment | -0.01 ± 0.11 | 0.02 ± 0.08 |
| Change From Baseline at Last Visit | 0.05 ± 0.09 | 0.10 ± 0.08 |
Vital sign measurements included measurements of respiratory rate, blood pressure, body temperature and pulse. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance. Only those categories with at least one participant with event are reported. As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan, Phase A: Placebo, Phase B: Prior Tolvaptan and Phase B: Prior Placebo).
| percentage of participants | Phase A: Tolvaptan | Phase A: Placebo | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|---|---|
| Pulse Rate (Beats per Minute [BPM]) <=50 and Decrease from Baseline >=15 | 0.0 | 2.3 | 0.0 | 5.3 |
| Systolic Blood Pressure (millimetre of mercury [mmHg]) >=130 and Increase from Baseline >=20 | 2.1 | 0.0 | 0.0 | 0.0 |
| Systolic Blood Pressure (mmHg) <=120 and Decrease from Baseline >=20 | 4.2 | 7.0 | 9.5 | 10.3 |
| Systolic Blood Pressure (mmHg) >=144 and Increase from Baseline >=20 | 2.1 | 2.3 | 0.0 | 2.6 |
| Diastolic Blood Pressure (mmHg) <=50 and Decrease from Baseline >=15 | 4.2 | 7.0 | 9.5 | 0.0 |
| Diastolic Blood Pressure (mmHg) >=86 and Increase from Baseline >=15 | 0.0 | 0.0 | 7.1 | 0.0 |
| Diastolic Blood Pressure (mmHg) <=80 and Decrease from Baseline >=15 | 12.5 | 18.6 | 16.7 | 12.8 |
| Diastolic Blood Pressure (mmHg) >=92 and Increase from Baseline >=15 | 0.0 | 4.7 | 4.8 | 2.6 |
Laboratory parameters=haematology,chemistry,urinalysis,\& LFTs.Criteria for laboratory abnormalities along with their test result grade=Increased creatinine level: Baseline(BSL):Grade 0,\>BSL-1.5xBSL:1,\>1.5-3xBSL:2,\>3-6xBSL:3,\>6xBSL:4.Decreased glucose level: \<30:-4,30-\<40:-3, 40-\<55:-2, 55-\<65:-1,\>=65:0; Increased:\<=115:0,\>115-160:1,\>160-250:2,\>250-500:3,\>500:4.Decreased potassium level: \<2.5:-4,2.5-\<3:-3,3-\<lower limit of normal(LLN):-1,LLN:0; Increased:upper limit of normal(ULN):0,\>ULN-5.5:1,\>5.5-6:2,\>6-7:3,\>7:4.Decreased sodium level: \<120:-4,120-124:-3,125-129:-2,130-135:-1,\>=136:0; Increased:\<=145:0,146-150:1,151-155:2,156-160:3,\>160:4. Increased triglyceride level:ULN:0,\>ULN-2.5xULN:1,\>2.5-5xULN:2,\>5-6xULN:3,\>6xULN:4. Decreased Neutrophils:\<0.5:-4,0.5-\<1:-3,1-\<1.5:-2,1.5-\<LLN:-1,LLN:0. Potentially clinically significant increase or decrease was defined as Baseline grade 0,1,-1 and post-baseline grade \>1, \<-1 or Baseline grade \>1,\<-1 and post-baseline grade \>or\<Baseline grade.
| percentage of participants | Phase A: Tolvaptan | Phase A: Placebo | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|---|---|
| Increase in Creatinine Level (mg/dL) | 8.3 | 0.0 | 7.1 | 7.7 |
| Decrease in Glucose Level (mg/dL) | 0.0 | 2.6 | 0.0 | 2.9 |
| Increase in Potassium Level (milliequivalents per deciliter [mEq/dL]) | 2.1 | 0.0 | 0.0 | 2.6 |
| Increase in Sodium Level (mEq/dL) | 0.0 | 0.0 | 0.0 | 2.6 |
| Increase in Triglyceride Level (mg/dL) | 0.0 | 0.0 | 3.1 | 0.0 |
| Decrease in Neutrophils (10^9/L) | 0.0 | 4.9 | 5.0 | 2.6 |
An AE was defined as any untoward medical occurrence in a participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Aquaretic AEs included Medical Dictionary for Regulatory Activities \[MedDRA\] preferred terms of thirst, polyuria (production of large volumes of dilute urine), nocturia (need to wake up to urinate at night), pollakiuria (abnormally frequent urination), and polydipsia (excessive thirst). As prespecified in the protocol, data for safety is reported by the treatment group (Phase A: Tolvaptan, Phase A: Placebo, Phase B: Prior Tolvaptan and Phase B: Prior Placebo).
| percentage of participants | Phase A: Tolvaptan | Phase A: Placebo | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|---|---|
| Phase A and B: Percentage of Participants With Aquaretic Adverse Events (AEs) | 64.6 | 16.3 | 14.3 | 48.7 |
Collected over From the first dose of study drug up to 14 days post last dose (up to approximately 37 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase A: Tolvaptan | 0/48 (0%) | 1/48 (2.1%) | 45/48 (93.8%) |
| Phase A: Placebo | 0/43 (0%) | 6/43 (14%) | 42/43 (97.7%) |
| Phase B: Prior Tolvaptan | 0/42 (0%) | 7/42 (16.7%) | 38/42 (90.5%) |
| Phase B: Prior Placebo | 0/39 (0%) | 8/39 (20.5%) | 39/39 (100%) |
| Event | Phase A: Tolvaptan | Phase A: Placebo | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 0/48 | 0/43 | 0/42 | 2/39 |
| COVID-19Infections and infestations | 0/48 | 0/43 | 2/42 | 0/39 |
| Abdominal painGastrointestinal disorders | 0/48 | 0/43 | 1/42 | 1/39 |
| Arthritis bacterialInfections and infestations | 0/48 | 0/43 | 0/42 | 1/39 |
| Expired product administeredInjury, poisoning and procedural complications | 0/48 | 0/43 | 0/42 | 1/39 |
| Alanine aminotransferase increasedInvestigations | 0/48 | 0/43 | 1/42 | 1/39 |
| Heart rate increasedInvestigations | 0/48 | 0/43 | 0/42 | 1/39 |
| SARS-COV-2 test positiveInvestigations | 0/48 | 0/43 | 1/42 | 1/39 |
| Eating disorderPsychiatric disorders | 0/48 | 0/43 | 0/42 | 1/39 |
| Renal impairmentRenal and urinary disorders | 0/48 | 0/43 | 1/42 | 1/39 |
| Event | Phase A: Tolvaptan | Phase A: Placebo | Phase B: Prior Tolvaptan | Phase B: Prior Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 16/48 | 21/43 | 15/42 | 17/39 |
| NasopharyngitisInfections and infestations | 10/48 | 14/43 | 11/42 | 13/39 |
| PolyuriaRenal and urinary disorders | 13/48 | 2/43 | 2/42 | 13/39 |
| Abdominal painGastrointestinal disorders | 6/48 | 3/43 | 4/42 | 12/39 |
| RhinitisInfections and infestations | 3/48 | 3/43 | 11/42 | 4/39 |
| VomitingGastrointestinal disorders | 7/48 | 10/43 | 5/42 | 7/39 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 4/48 | 6/43 | 9/42 | 7/39 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/48 | 5/43 | 7/42 | 8/39 |
| PyrexiaGeneral disorders | 4/48 | 3/43 | 8/42 | 7/39 |
| Blood creatinine increasedInvestigations | 9/48 | 2/43 | 7/42 | 5/39 |
The Randomized Sample included all participants who were randomized in the trial.
| Age, Continuous(years) | Phase A: Tolvaptan | Phase A: Placebo | Total |
|---|---|---|---|
| Mean | 12.9 ± 3.2 | 12.8 ± 2.8 | 12.9 ± 3.0 |
| Sex: Female, Male(Participants) | Phase A: Tolvaptan | Phase A: Placebo | Total |
|---|---|---|---|
| Female | 21 | 23 | 44 |
| Male | 27 | 20 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Phase A: Tolvaptan | Phase A: Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 47 | 42 | 89 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase A: Tolvaptan | Phase A: Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 46 | 42 | 88 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Sep 2016 to primary completion in Nov 2021, 61 months.
Results were first posted in Jan 2023, 1 year 1 month after primary completion. A results delay was requested in Nov 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Polycystic Kidney, Autosomal Dominant →
Otsuka Pharmaceutical Development & Commercialization, Inc. →